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Background: Proinflammatory cytokine interleukin-1β (IL-1β) released from spinal microglia plays an important role
in the maintenance of acute and chronic pain states. However, the cellular basis of this action remains poorly
understood. Using whole-cell patch-clamp recordings, we examined the action of IL-1β on AMPA- and NMDA-
receptor-mediated currents recorded from substantia gelatinosa (SG) neurons of adult rat spinal cord slices which
are key sites for regulating nociceptive transmission from the periphery.
Results: AMPA- and NMDA-induced currents were increased in peak amplitude by IL-1β in a manner different from
each other in SG neurons. These facilitatory actions of IL-1β were abolished by IL-1 receptor (IL-1R) antagonist (IL-
1ra), which by itself had no detectable effects on AMPA- and NMDA-induced currents. The AMPA- but not NMDA-
induced current facilitated by IL-1β was recovered to control level 30 min after IL-1β washout and largely
depressed in Na+-channel blocker tetrodotoxin-containing or nominally Ca2+-free Krebs solution. Minocycline, a
microglia inhibitor, blocked the facilitatory effect of IL-1β on AMPA- but not NMDA-induced currents, where
minocycline itself depressed NMDA- but had not any effects on AMPA-induced currents.
Conclusions: IL-1β enhances AMPA and NMDA responses in SG neurons through IL-1R activation; the former but
not latter action is reversible and due to an increase in neuronal activity in a manner dependent on extracellular
Ca2+ and minocycline. It is suggested that AMPA and NMDA receptors are positively modulated by IL-1β in a
manner different from each other; the former but not latter is mediated by a neurotransmitter released as a result
of an increase in neuronal activity. Since IL-1β contributes to nociceptive behavior induced by peripheral nerve or
tissue injury, the present findings also reveal an important cellular link between neuronal and glial cells in the spinal
dorsal horn.
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Interleukin-1β (IL-1β), a 17.5-kDa polypeptide proin-
flammatory cytokine, is believed to play an important
role in modulating neuronal excitability in the peripheral
and central nervous systems (PNS and CNS, respectively)
in addition to its immunoregulatory effects [1-4]. Recently,
IL-1β is of special interest as it is released under condi-
tions associated with persistent pain including peripheral* Correspondence: liutaomm@hotmail.com; kumamote@cc.saga-u.ac.jp
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reproduction in any medium, provided the ortissue injury (inflammatory pain) [5-8] and peripheral
nerve injury (neuropathic pain) [9-12]. In animal models
of neuropathic pain, IL-1β mRNA and protein are up-
regulated immediately or as long as 35 days post-surgery
[10,11,13], concomitantly with the development of hyper-
algesia (an increase in sensitivity to noxious stimuli) and
allodynia (a pain sensation in response to light-touch).
Numerous reports have shown that IL-1β is an extremely
potent mechanical and thermal hyperalgesic agent when
injected into any peripheral tissues [14-20]. For example,
IL-1β increases the heat-evoked release of calcitonin gene-
related peptide (CGRP) from rat cutaneous nociceptors
[17], sensitizes cultured dorsal root ganglion (DRG) neu-
rons to noxious heat by potentiating heat-activated inwardThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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neurons in rats [22,23].
Accumulating evidence suggests that IL-1β is involved
in pain sensation via not only peripheral but also central
mechanisms such as the enhancement of nociceptive
neuronal excitation in the CNS. This is in agreement with
literatures suggesting that IL-1β produces hyperalgesia and
allodynia when administered intracerebra-ventricularly or
intrathecally [24-28]. Although the source of increased IL-
1β in the CNS is not clear, spinal IL-1β may be produced
by glial cells (e.g., microglia and astrocytes) in different
chronic pain states [5,11,29,30]. Blocking the activation of
spinal cord glial cell prevents or delays the development of
persistent pain [31]. These findings strongly indicate that
over-expression of IL-1β in the CNS may be involved in
glia-related persistent pain. Besides, several studies demon-
strated that IL-1β directly modulates neuronal activity. For
example, IL-1β contributed to a membrane depolarization
of paraventricular nucleus neurons [32] or a membrane
hyperpolarization of hypothalamic neurons [33]. Further-
more, IL-1 receptor type I (IL-1RI) is localized in the
superficial layers of the spinal dorsal horn, an area which
plays a pivotal role in modulation of pain transmission
[29]. Mice genetically-impared in IL-1 signaling (e.g., a de-
letion of IL-1RI or IL-1 receptor accessory protein and an
over-expression of IL-1R antagonist (IL-1ra)) exhibited a
reduction in the extent of thermal hyperalgesia and mech-
anical allodynia, compared to wild-type (WT) controls
[34-36]. It is possible that the effect of IL-1β on pain trans-
mission could be directly mediated by an interaction with
IL-1RI in the superficial dorsal horn neuron.
The substantia gelatinosa (SG; lamina II of Rexed) of
the spinal dorsal horn receives nociceptive information
from the viscera, skin and other organs through fine
myelinated Aδ and unmyelinated C primary-afferent fi-
bers [37]. Nociceptive information is modulated by a
variety of endogenous systems in the spinal dorsal horn
and then transferred to the CNS. It has been shown that
activity-dependent modulation of α-amino-3-hydroxy-5-
methyl-4-isoxazole-4-propionic acid (AMPA) and N-me-
thyl-D-aspartate (NMDA) receptors in SG neurons
greatly contributes to persistent pain development [38].
Electrophysiological findings have provided evidence
that exogenous acute application of IL-1β enhances
AMPA- or NMDA-induced currents in SG neurons [39].
However, the underlying cellular mechanism remains
unclear. Current evidence suggested that IL-1β is in-
volved in not only acute but also chronic pain. It is
reported that IL-1β facilitates inflammatory pain by en-
hancing phosphorylation of NMDA receptor NR1 sub-
unit [29]. This observation strongly indicates that IL-1β
may have long-term actions on glutamatergic synaptic
transmission in SG neurons. Since AMPA and NMDA
receptors were modulated in a manner distinct fromeach other [38], we hypothesized that the enhancements
of AMPA- and NMDA-induced currents produced by
IL-1β in SG neurons are IL-1RI dependent while being
different in cellular mechanism. We also thought that
the IL-1β effects may be influenced by inhibition of glial
activation. Spinal cord slice preparations show preserved
local neuronal networks and thus have proved to be use-
ful in analyzing the mechanisms of pain transmission.
The aim of the present study is to provide additional evi-
dence for the cellular mechanism of the effects of IL-1β
on the AMPA and NMDA responses in SG neurons by
using blind whole-cell patch-clamp recordings from adult
rat spinal cord slices.
Results
Whole-cell patch-clamp recordings were made from a
total of 82 SG neurons. Stable recordings could be
obtained from slices maintained for more than 12 h after
the dissection, and recordings were made from single
SG neurons for up to 4 h. All SG neurons tested had
resting membrane potentials more negative than −50
mV (when measured in the current-clamp mode).
AMPA- and NMDA-induced currents are enhanced by IL-
1β in SG neurons
Exogenous application of AMPA (5 μM) for 30 s in-
duced an inward current at a holding potential of −70
mV. After 3 min pretreatment of IL-1β (10 ng/ml, in this
and subsequent experiments, a total of its superfusion
time depended on when the agonist-induced current
returned to original level, usually 5–7 min), the peak amp-
litude of AMPA-induced current increased to 148 ± 22%
(n = 12, P < 0.05) of control (139 ± 27 pA, Figure 1A), and
returned to 110 ± 10% (n = 9, P > 0.05) of initial values
(139 ± 36 pA) after IL-1β was washed out for 30 min
(Figure 1A). Bath-applied NMDA (50 μM) for 30 s elicited
an inward current at a holding potential of −50 mV (since
opening of NMDA receptor-channel requires both its
agonist and depolarization to relieve its block by Mg2+ for
its activation). In the presence of IL-1β, the mean ampli-
tude of NMDA-induced current enhanced to 158 ± 13%
(n = 7, P < 0.05) of control (49 ± 12 pA, Figure 1B). These
values were further increased to 170 ± 31% (n = 4, P <
0.05) of initial values (45 ± 12 pA) 30 min later after wash-
out of IL-1β (Figure 1B), suggesting an irreversible effect
of IL-1β on NMDA receptors. This indicates that the fa-
cilitatory effect of IL-1β on NMDA-induced currents lasts
for at least 30 min even in the absence of this cytokine.
Therefore, mechanisms underlying the facilitatory effects
of IL-1β on postsynaptic AMPA and NMDA receptors
may be different from each other. The effects of IL-1β on
AMPA- and NMDA-induced currents were summarized
in Figure 1C, which were examined in 12 and 7 neurons,




















































Figure 1 Enhancement by IL-1β of AMPA- and NMDA-induced currents in rat substantia gelatinosa (SG) neurons. (A) Recordings of
AMPA-induced inward currents, which were enhanced in the presence of IL-1β and recovered at 30 min after its washout. Drug application is
marked with bars. (B) Recordings of NMDA-induced inward currents, which were enhanced by IL-1β; this enhancement persisted at 30 min after
its washout. (C) Bar graphs showing the averaged peak amplitude of AMPA (left, n = 12)- and NMDA (right, n = 7)-induced currents under the
treatment with IL-1β (black bar) and after its washout (gray bar), relative to those before this treatment (control, open bar). In this and
subsequent figures, vertical lines accompanied by bars indicate SEM; *: P < 0.05, compared with control; n.s.: not significant (t test). In this and
subsequent figures, the concentrations of IL-1β used was 10 ng/ml; the concentrations of AMPA and NMDA used were 5 and 50 μM, respectively;
the AMPA and NMDA responses were induced at holding potentials (HPs) of −70 and −50 mV, respectively.
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potentiation of AMPA- (12 out of 19 neurons, 63%) and
NMDA-induced (7 out of 8 neurons, 88%) currents.
The enhancement by IL-1β of AMPA- and NMDA-induced
currents is IL-1 receptor-dependent
IL-1β exerts its actions by binding to IL-1RI. To assess
whether the effects of IL-1β on AMPA- and NMDA-
induced currents in SG neurons were mediated by IL-
1RI, we examined the actions of IL-1β in the presence of
recombinant human IL-1ra. In these experiments, IL-1ra
(50 ng/ml) was applied 3 min before treatment with IL-
1β, and the drug remained present while the agonist was
being applied and the subsequent stimulation with
AMPA or NMDA. IL-1ra per se had no significant ef-
fects on AMPA- or NMDA-induced currents, and the
amplitudes of the currents were, respectively, 104 ± 15%
(n = 8, P > 0.05) of control (115 ± 40 pA, Figure 2A)
and 111 ± 8% (n = 9, P > 0.05) of control (51 ± 16 pA,
Figure 2B). Moreover, IL-1ra blocked the responses ofIL-1β in all the neurons tested (Figure 2A, B). Ampli-
tudes of the inward currents elicited by exogenous
AMPA and NMDA applied in the presence of IL-1β in
Krebs solution containing IL-1ra were, respectively, 97 ±
10% (n = 5, P > 0.05) of control (120 ± 26 pA, Figure 2A)
and 107 ± 9% (n = 4, P > 0.05) of control (60 ± 20 pA,
Figure 2B). Because excitatory transmission is mainly
mediated by AMPA and NMDA receptors in SG neu-
rons, these results indicate that the excitatory effects of
IL-1β, which are significantly blocked by IL-1ra, are due
to a direct activation of IL-1RI. Figure 2C summarizes
the effects of IL-1β on AMPA- and NMDA-induced cur-
rents in the presence of IL-1ra, which are examined in 8
and 9 neurons, respectively.
Characterization of the IL-1β effect on AMPA- and NMDA-
induced currents
Since the function of postsynaptic AMPA and NMDA re-
ceptors can also be affected by any neuromodulators re-





















































Figure 2 AMPA- and NMDA-induced current amplitude increase produced by IL-1β was reduced in extent by IR-1ra. (A, B) Recordings of
AMPA (A) or NMDA (B)-induced currents in Krebs solution without drugs (left), with IL-1ra (50 ng/ml) alone (middle) and both IL-1ra and IL-1β
(right); they were obtained from the same neuron. In each of (A) and (B), all recordings were obtained from the same neuron. (C) Peak amplitude
of AMPA (left, n = 8)- and NMDA (right, n = 9)-induced currents in Krebs solution containing IL-1ra only (black bar) and together with IL-1β (gray
bar), relative to those without IL-1ra and IL-1β (control, open bar).
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AMPA- and NMDA-induced current amplitude increase
produced by IL-1β. Figures 3A and B demonstrate the ef-
fects of IL-1β on AMPA- and NMDA-induced currents,
respectively, in Krebs solution containing a Na+-channel
blocker tetrodotoxin (TTX; 0.5 μM). IL-1β did not affect
AMPA-induced current under a pretreatment with TTX
(100 ± 10% (n = 7, P > 0.05) of control (122 ± 37 pA),
Figure 3A). In contrast, even in the presence of TTX, neu-
rons showed a significant increase in NMDA-induced
current amplitude after IL-1β treatment (145 ± 10% (n = 7,
P < 0.05) of control (48 ± 8 pA), Figure 3B). Unlike the ef-
fect of IL-1β on NMDA-induced current in the absence of
TTX (Figure 1B), IL-1β modulation of the NMDA re-
sponse was moderately increased after its removal in the
presence of TTX (128 ± 15% (n = 5, P > 0.05) of control
(69 ± 12 pA), Figure 3B, C). Hence, TTX prevented the fa-
cilitatory effect of IL-1β on AMPA-induced currents while
having no effect on NMDA ones. Figure 3C summarizes
the effects of IL-1β on AMPA- and NMDA-induced
currents in the presence of TTX, each of which effects is
examined in 7 neurons. These results suggest that thepotentiation of AMPA but not NMDA current is due to an
increase in neuronal activity.
Since the release of neuromodulators involving in the
IL-1β effect from any neurons requires intracellular Ca2+,
we next examined whether the potentiating effect of IL-1β
was dependent on extracellular Ca2+. In all neurons exam-
ined, AMPA-induced currents were not increased in
amplitude by IL-1β in a Ca2+-free bath solution (88 ±
8% (n = 5, P > 0.05) of control (68 ± 13 pA), Figure 4A).
However, NMDA-induced current amplitudes were in-
creased by IL-1β in the presence of Ca2+-free bath solu-
tion (178 ± 26% (n = 7, P < 0.05) of control (18 ± 5 pA),
Figure 4B), and this increase was moderately enhanced
30 min after washout of IL-1β (146 ± 24% (n = 6, P >
0.05) of control (29 ± 6 pA), Figure 4B). These findings
indicate that the effect of IL-1β on AMPA- but not
NMDA-induced current may be due to an increase in
intracellular Ca2+ concentration originating from extra-
cellular Ca2+. Figure 4C summarizes the effects of IL-1β
on AMPA- and NMDA-induced currents in Ca2+-free


















































Figure 3 Tetrodotoxin (TTX) reduced the AMPA- but not NMDA-induced current amplitude increase produced by IL-1β. (A) Recordings
of AMPA-induced currents in the absence and presence of IL-1β in Krebs solution containing TTX (0.5 μM); they were obtained from the same
neuron. (B) Recordings of NMDA-induced currents in the absence and presence of IL-1β in Krebs solution containing TTX (0.5 μM); they were
obtained from the same neuron. (C) The averaged peak amplitude of AMPA (left, n = 7)- and NMDA (right, n = 7)-induced currents in the
presence of IL-1β (black bar), relative to those before the application of IL-1β (control, open bar), in Krebs solution containing TTX.
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are modulated by glial activation
Since both neuronal and glial cells are shown to express
IL-1R [40], activation of IL-1R in glial cells may be im-
plicated in persistent hyperalgesia. To know whether the
modulation by IL-1β of AMPA and NMDA response is
mediated by glial activation, we investigated the effect of
a microglia inhibitor minocycline (20 μM) on the IL-1β
mediated responses in SG neurons. As illustrated in
Figure 5A and B, the potentiation of the inward current
evoked by AMPA but not NMDA in the presence of IL-
1β was inhibited in extent by minocycline. The percent
values were, respectively, 95 ± 11% (n = 6, P > 0.05) of
control (100 ± 14 pA, Figure 5A) and 155 ± 15% (n = 5,
P < 0.05) of control (46 ± 17 pA, Figure 5B). The facili-
tatory action of IL-1β on NMDA current moderately
persisted 30 min after washout of IL-1β in the presence
of minocycline [174 ± 58% (n = 4, P > 0.05) of control
(92 ± 30 pA), not shown]. It is important to note that
minocycline per se inhibited the NMDA- (71 ± 7% (n =
6, P < 0.05) of control (63 ± 19 pA), Figure 5B) but notAMPA-induced current (117 ± 8% (n =5, P > 0.05) of con-
trol (82 ± 16 pA), Figure 5A). These results suggest that
glial cells located in the spinal dorsal horn play an import-
ant role in pain transmission conveyed by IL-1β. Figure 5C
summarizes the effects of IL-1β on AMPA- and NMDA-
induced currents in the presence of minocycline, which
are examined in 6 and 5 neurons, respectively. These re-
sults together indicate that microglia activation in the
spinal dorsal horn may be involved in the IL-1β induced
sensitization of SG neurons.
Discussion
In the present study, we investigated the effect of IL-1β
on AMPA- and NMDA-induced currents in SG neurons
by using whole-cell patch-clamp recordings. Our study
shows the enhancement by IL-1β of both postsynaptic
AMPA and NMDA receptor responses which has been
reported previously [39]. Moreover, our data reveal that
these facilitatory effects of IL-1β on AMPA and NMDA
receptors may reflect different mechanisms. Importantly,
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Figure 4 AMPA- but not NMDA-induced current amplitude increase by IL-1β depended on extracellular Ca2+. (A) Recordings of AMPA-
induced currents in the absence and presence of IL-1β in a nominally Ca2+-free Krebs solution; they were obtained from the same neuron.
(B) Recordings of NMDA-induced currents in the absence and presence of IL-1β in a nominally Ca2+-free Krebs solution; they were obtained from
the same neuron. (C) Averaged peak amplitude of AMPA (left, n = 5)- or NMDA (right, n = 7)-induced currents in the presence of IL-1β (black
bar), relative to those in the absence of IL-1β (control, open bar), in Ca2+-free solution.
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responses to exogenously-applied AMPA or NMDA.
Our data further provide new and important evidence that
microglia activation may be involved in the glutamate-
receptor response potentiations produced by IL-1β.
The role of ionotropic glutamate receptors (mainly
AMPA and NMDA receptors in SG neurons) as targets
of analgesics has emerged during the last decade. It has
been reported that the activation of NMDA receptors
critically contributes to the development of chronic
nociceptive hypersentivity following peripheral tissue
damage or nerve injuries [41]. Recently, some studies
have also shown a contribution of spinal AMPA receptors
in the development of both acute and chronic painful con-
ditions [42,43]. There is still an ongoing controversy
whether IL-1β signaling is involved in pain transmission
under normal, non-inflammatory states. When injected
intrathecally into intact rats, IL-1β is reported to be with-
out effect [20,44]. However, our study clearly demon-
strates that acute application of IL-1β rapidly alters the
efficacy of extrasynaptic AMPA and NMDA receptors in
SG neurons of spinal cord slices. This may explain the fact
that intrathecal administration of IL-1β in healthy rats in-
duces hyperalgesia and allodynia and enhances wind-upactivity in dorsal horn neurons [45]. Recently, several
groups of SG neurons with distinct electrophysiological
properties were characterized [46,47]. Although we cannot
be sure that the excitatory actions of IL-1β in our study
are exerted on excitatory interneurons, it is generally
believed that most neurons recorded in the SG are exci-
tatory [48,49]. In addition, IL-1β has been reported to
depolarize paraventricular nucleus neurons [32] or to
hyperpolarize hypothalamic neurons [33], but this was
not the case in SG neurons, because currents required
to hold membrane potentials at −70 or −50 mV were
unaffected by IL-1β. In accordance with data showing
that IL-1β increases NMDA receptor-mediated rise in
intracellular calcium levels in hippocampal neurons [50]
and enhances NMDA-induced current in cultured hip-
pocampal [51] or SG neurons [39], our data also dem-
onstrated an enhancement of NMDA current by IL-1β.
Although it was reported that AMPA-induced current
was moderately enhanced by IL-1β (P > 0.05) [39], our
data demonstrated that it was significantly enhanced by
IL-1β. This discrepancy may be due to a longer super-
fusion time of IL-1β in our studies and indicate that the
effects of IL-1β on neurons depend on not only the type


























































Figure 5 AMPA- but not NMDA-induced current amplitude increase by IL-1β disappeared in the presence of minocycline. (A, B)
Recordings of AMPA (A) or NMDA (B)-induced currents in Krebs solution without drugs (left), with minocycline (20 μM) alone (middle) and both
minocycline and IL-1β (right). In each of (A) and (B), all recordings were obtained from the same neuron. (C) Bar graphs showing the averaged
peak amplitudes of AMPA (left, n=6)- and NMDA (right, n=5)-induced currents in the presence of IL-1β (gray bar), relative to those in the absence
of IL-1β (black bar), in Krebs solution containing minocycline. Note that minocycline itself inhibited NMDA- but not AMPA-induced currents
(compared to control, open bar).
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confirm that IL-1β exhibited a persistent facilitatory ef-
fect on postsynaptic NMDA but not AMPA receptor
function after removal of this cytokine. Thus, IL-1β may
activate a postsynaptic process linked to long-term po-
tentiation (LTP) through NMDA receptors which might
have functional relevance for hyperalgesia or allodynia.
This supports the report that IL-1β produced a thermal
hyperalgesia lasting for 24 h after its intrathecal injec-
tion [26].
IL-1RI, which is known to mediate all biological func-
tions of IL-1β [52], was detected in most of large and
small DRG neurons as well as in some glia-like cell types
by in situ hybridization staining [53]. Another double
immunofluorescence labeling study showed that IL-1RI
and NMDA receptor NR1 subunit are co-localized in
the spinal dorsal horn [29]. Consistently, acute or chronic
administration of IL-1ra, the endogenous antagonist of the
IL-1R, which competitively blocks the binding of IL-1β to
the receptor without inducing a signal of its own [54], in-
hibits a hypernociception induced by IL-1β [16,19,55-57].Thus, inhibition of IL-1β signaling such as blockade of IL-
1RI by IL-1ra in spinal dorsal horn neurons could account
for its antinociceptive action and decrease the function of
excitatory transmission in pain pathway. In agreement
with these reports, our present data demonstrate that IL-
1ra inhibits AMPA- and NMDA-induced current in-
creases produced by IL-1β in all the neurons tested. Based
on reports that NMDA receptors have an essential role in
pain hypersensitization, our findings provide new and im-
portant evidence that inhibition by IL-1ra of NMDA re-
ceptor potentiation produced by IL-1β could prevent
plasticity-related phenomena such as central sensitization
or excitotoxicity. Actually, IL-1ra prevents the develop-
ment of LTP, presumably by inhibiting NMDA receptor
phosphorylation. An immunohistochemical study demon-
strated that IL-1ra inhibited spinal cord phosphorylation
of NR1 in a rat model of inflammatory pain [29]. In an-
other study, IL-1ra abolished NMDA-induced intracellular
Ca2+ level increases produced by IL-1β, which may be in-
volved in preventing tyrosine phosphorylation of NMDA
receptor NR2A/B subunit [50]. Compared to cultured or
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used in the present study have the advantage of offering
recording under conditions closer to physiological ones.
Our electrophysiological experiment data provide a cellu-
lar mechanism that IL-1RI may be a target for treatment
of inflammatory and neuropathic pain.
Several cellular mechanisms could be involved in the
enhancement of postsynaptic AMPA and NMDA recep-
tor responses by IL-1β, e.g., presynaptic transmitter re-
lease, the modulation of the receptors in quantity (via a
change in trafficking) and efficacy. It has been observed
that IL-1β could increase the release of glutamate through
an increase in Ca2+ influx in hippocampal neurons [58].
The present study also demonstrates that the facilitatory
effect of IL-1β on postsynatpic AMPA receptors was
TTX-sensitive and Ca2+-dependent since AMPA-induced
current increased by IL-1β was abolished in the presence
of TTX or Ca2+-free Krebs solution. Consistent with the
report that IL-1β increased the frequency and amplitude
of spontaneous excitatory postsynaptic currents (sEPSCs)
in SG neurons [39], our data indicated that the enhance-
ment of AMPA responses may be generated by glutamate-
receptor activation and neuronal activity increase, possibly
by the facilitatory effect of IL-1β on intracellular Ca2+ level
elevation. On the other hand, NMDA receptor response
facilitation produced by IL-1β was resistant to TTX or
Ca2+-free, indicating a direct action on postsynaptic
NMDA receptor. The glutamate-mediated excitatory
transmission efficiency is dependent on the number and
function of AMPA or NMDA receptors at glutamatergic
synapses. It is difficult from our data to know postsynaptic
AMPA or NMDA receptor regulation such as receptor
trafficking or subunit phosphorylation by IL-1β, but our
findings are consistent with previous studies that the
former is probably associated with a presynaptic mechan-
ism of glutamate release increase while the latter is medi-
ated by NMDA receptor subunit phosphorylation.
IL-1β is a cytokine released from spinal glial cells in
response to pathophysiological changes that occur dur-
ing different disease states, such as inflammatory and
neuropathic pain. Initial reports suggested that IL-1β is
an extremely potent hyperalgesic agent when injected
systemically, intraperitoneally or intraplantarly in rats
[14]. These results may be in accordance with literatures
reporting that activation of microglia and astrocyte may
be involved in neuropathic pain [59,60] and strongly
suggest signaling via IL-1β between neuronal and glial
cells might occur. Our results showed that in the presence
of a microglia inhibitor minocycline, AMPA-induced
current amplitude increase mediated by IL-1β was inhibited
without any changes by minocycline itself. In contrast,
NMDA-induced current facilitation produced by IL-1β was
not affected by minocycline. Minocycline-sensitive micro-
glia may be activated by neurotransmitters released as aresult of an increase in neuronal activity, resulting in an en-
hancement of AMPA but not NMDA response. This issue
remains to be further addressed. Furthermore, we reported,
for the first time, that minocycline per se depressed
NMDA-induced current. This inhibitory action may be due
to an open-channel block by minocycline itself, as shown
for GluR2 homomeric channels [61]. Further research is
needed to elucidate the molecular mechanism underlying
this NMDA receptor inhibition by minocycline in SG neu-
rons. Consistent with others’ data, our study indicates the
realization that glia-derived signaling molecules such as IL-
1β can contribute to and modulate pain signaling in the
spinal cord.
Conclusions
In summary, we demonstrate novel glia-neuron mecha-
nisms by which acute application of IL-1β directly en-
hances AMPA- and NMDA-receptor responses in a
subpopulation of SG neurons in rat spinal cord slice
preparations, effects that are a result of the activation of
IL-1RI by this cytokine and also of microglial cells.
Specifically, the potentiation by IL-1β of postsynaptic
NMDA but not AMPA receptors persisted. This distinct
plastic change suggests that IL-1β exerts a crucial role in
not only acute but also pathological pain sensation. IL-
1ra and microglia inhibitors may be useful candidates
for the treatment of pain.
Methods
All animal experiments were approved by the Animal
Care and Use Committee of Saga University (Saga,
Japan) and were conducted in accordance with the UK
Animals (Scientific Procedures) Act of 1986 and associ-
ated guidelines.
Spinal cord slice preparation
The methods used to obtain adult rat spinal cord slices
were similar to those used in our previous studies [62-65].
In brief, male adult Sprague–Dawley rats (6–8 wk old,
200–300 g) were anesthetized with urethane (1.2 g/kg, in-
traperitoneal), and then a laminectomy was performed to
extract a lumbosacral spinal cord enlargement (L1–S3).
The spinal cord was removed and placed in preoxygenated
ice-cold (1–3°C) Krebs solution. Immediately after the re-
moval of the spinal cord, the rats were given an overdose
of urethane and then sacrificed by exsanguination. The
pia-arachnoid membrane was removed after cutting all
the ventral and dorsal roots near the root entry zone. The
spinal cord was mounted on a vibrating microslicer
(DTK-1000; Dousaka, Kyoto, Japan), and several 600-μm
-thick transverse slices were cut. One of the slices was
placed on a nylon mesh in the recording chamber (vol-
ume: 0.5 ml) and then perfused at a rate of 10–15 ml/min
with Krebs solution saturated with 95% O2 and 5% CO2,
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solution used was as follows (in mM): 117 NaCl, 3.6 KCl,
2.5 CaCl2, 1.2 MgCl2, 1.2 NaH2PO4, 25 NaHCO3, and 11
glucose (pH = 7.4 when saturated with the gas). The
remaining slices were stored under similar conditions
until use. Typically, one neuron was studied per slice to
observe the effect of IL-1β.
Patch-clamp recordings from SG neurons
The SG was identified as a translucent band under a
binocular microscope with light transmitted from below
[62-64]. Blind whole-cell patch-clamp recordings were
performed from neurons located at the center of SG to
avoid recordings from the laminae I and III neurons.
Patch pipettes were fabricated from thin-walled, fiber-
filled capillaries (1.5 mm OD, World Precision Instru-
ments, USA) and contained the following solutions (in
mM): 135 K-gluconate, 5 KCl, 0.5 CaCl2, 2 MgCl2, 5
EGTA, 5 HEPES, and 5 Mg-ATP (pH = 7.2). The patch
pipettes had a resistance of 8–12 MΩ. Signals were ac-
quired using an Axopatch 200B amplifier (Molecular
Devices, Sunnyvale, CA, USA). Currents obtained in the
voltage-clamp mode were low pass filtered at 5 kHz and
digitized at 333 kHz with an analog-to-digital converter
(Digidata 1322A, Molecular Devices). Holding potential
was set to −70 mV for recording exogenous AMPA current.
Exogenous NMDA current was recorded at −50 mV. The
data were stored and analyzed with a personal computer
using pCLAMP v 9.2 software (Molecular Devices).
Application of drugs
Drugs were applied by perfusion via a three-way stop-
cock without an alteration in the perfusion rate or
temperature. The solution in the recording chamber
having a volume of 0.5 ml was completely replaced
within 15 s. The drugs used were IL-1β (rat recombin-
ant), IL-1ra (human, Cedarlane Laboratories Ltd, ON,
Canada), AMPA (Tocris Cookson, Bristol, UK), NMDA,
minocycline hydrochloride (Sigma-Aldrich, St. Louis,
MO, USA) and TTX (Wako, Osaka, Japan). These drugs
(except for IL-1β and IL-1ra) were first dissolved in dis-
tilled water at 1,000 times the concentration to be used
and then stored at −20°C. 1000x stock solutions of IL-1β
and IL-1ra were prepared in phosphate buffered saline
(PBS) containing 1% bovine serum albumin (BSA)
(Sigma-Aldrich) and stored at −20°C. The stock solution
was diluted to the desired concentration in Krebs solution
immediately before use. To prevent a desensitization of
AMPA and NMDA receptor during bath application of
agonist to slices, time intervals between the repetitive ap-
plication of AMPA and NMDA were > 30 min. The tub-
ing of our perfusion system was coated with AquaSil
siliconizing fluid (Thermo Fisher Scientific, USA) to re-
duce the loss of IL-1β and IL-1ra through nonspecificinteractions. The tonicity of the nominally Ca2+-free,
high-Mg2+ (5 mM) Krebs solution was adjusted by lower-
ing the Na+ concentration of the Krebs solution.Statistical analysis
Numerical data are presented as the means ± SEM. Stat-
istical significance was determined as P < 0.05 using the
Student's paired t-test to compare groups treated or
non-treated with IL-1β. In all cases, n refers to the num-
ber of neurons recorded.
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